Adults with persistent inflammatory acne gained no clear winner from IPL, pulsed dye laser (PDL), or Q-switched Nd:YAG 1064-nm laser in a 2026 three-arm pilot. Inflammatory acne means red, swollen papules and pustules, and all three light-based options lowered lesion counts and severity scores without a significant gap between groups.
U.S. National Library of Medicine / PubMed reports the pilot enrolled 36 patients with moderate-to-severe inflammatory acne and assigned them to IPL, PDL, or Q-switched Nd:YAG to compare efficacy and safety the 2026 three-arm trial record. Scores fell inside each arm during treatment, and daily-life impact also eased.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 36-person pilot compared
- Did symptoms, daily life, and pain differ?
- How do earlier laser results fit?
- How should adults choose a device?
What the 36-person pilot compared
IPL uses broad pulses of filtered light. PDL uses a dye-based yellow beam that targets blood vessels. Q-switched Nd:YAG 1064-nm uses very short infrared pulses that reach deeper skin.
U.S. National Library of Medicine / PubMed reports no significant between-group differences in lesion counts or severity scores at any treatment session, with P-values from 0.06 to 0.92. Within each arm, lesion counts and severity scores fell significantly over the course. That pattern points to comparable clearance, not superiority.
Did symptoms, daily life, and pain differ?
Acne-related disability eased from baseline to two weeks after the final treatment. The Cardiff Acne Disability Index, a questionnaire about embarrassment, social interference, and daily burden, decreased significantly across the study.
Pain and side effects separated the options more than clearance did. Biology Insights, summarizing the randomized comparison, reports the Q-switched Nd:YAG group had less procedural pain than IPL or PDL, while adverse effects occurred in all groups summary of procedural pain and safety. Expect redness, swelling, crusting, or pigment change as possible short-term effects with any of the three.
How do earlier laser results fit?
A 2025 systematic review of vascular lasers for active inflammatory acne reported IPL lesion reductions of 42.40%-61.56%, according to U.S. National Library of Medicine / PubMed the 2025 systematic review of vascular lasers. The same review reported reductions up to 82.5% for PDL and as high as 83.5% for combined PDL/Nd:YAG. Those wider ranges came from varied studies, not the head-to-head pilot.
An earlier split-face randomized trial in mild-to-moderate acne found 1064-nm long-pulsed Nd:YAG and 595-nm PDL equally effective for inflammatory lesions and acne erythema. Erythema means lingering redness around healed or active spots. Nd:YAG-treated sides had fewer adverse effects in that trial, as reported by U.S. National Library of Medicine / PubMed.
How should adults choose a device?
Because no modality proved stronger clearance, choice can turn on fit rather than assumed power. The American Academy of Dermatology 2024 acne guidelines emphasize continued combination therapy with guideline-based topical or systemic care, via Practical Dermatology the AAD combination-therapy guidance.
Light treatment adds to care; it does not replace it. The pilot was small and short, with only 36 patients and disability follow-up two weeks post-treatment. Bring your pain tolerance, redness pattern, skin type, cost limits, and current prescriptions to that visit.
- pain tolerance and need for numbing or shorter recovery
- prominent redness, where a vascular-targeting PDL may appeal
- skin type and pigment-change risk
- cost, sessions, and clinic access
- current prescriptions and maintenance plan
You Might Also Like
- Microneedle Radiofrequency With Low-Dose Isotretinoin in 2026: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Treatment Response in the 2026 Cumulative Isotretinoin Dose Trial: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Concurrent Acne Procedures and Isotretinoin in 2026 Research: A Source-Checked 2026 Briefing for Adults With Persistent Acne